Paper41254792
Impact of TauroLock™-HEP500 versus unfractionated heparin for prevention of catheter complications in children with malignancy: a prospective, randomized, controlled study.
Eghbali A and 5 others. Eur J Med Res, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Impact of TauroLock™-HEP500 versus unfractionated heparin for prevention of catheter complications in children with malignancy: a prospective, randomized, controlled study. Papers, record 41254792. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41254792
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Impact of TauroLock™-HEP500 versus unfractionated heparin for prevention of catheter complications in children with malignancy: a prospective, randomized, controlled study.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anticoagulants | Major topic |
| Catheter-Related Infections | Major topic |
| Central Venous Catheters | Major topic |
| Heparin | Major topic |
| Taurine | Major topic |
| Thiadiazines | Major topic |
| Thrombosis | Major topic |
| Adolescent | |
| Child | |
| Child, Preschool | |
| Female | |
| Humans | |
| Infant | |
| Male | |
| C-Reactive Protein | |
| Catheterization, Central Venous | |
| Neoplasms | |
| Prospective Studies |
Source PubMed
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15677621 | Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. | Ann Oncol | 2005 | https://conductscience.org/library/papers/15677621 | PubMed |
| 2 | 40000988 | The effect of oral curcumin on vincristine-induced neuropathy in pediatric acute lymphoblastic leukemia: A double-blind randomized controlled clinical trial. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40000988 | PubMed |
| 3 | 32691665 | Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation. | J Vasc Access | 2021 | https://conductscience.org/library/papers/32691665 | PubMed |
| 4 | 30729550 | Human platelet antigens polymorphisms; association to the development of liver fibrosis in patients with chronic hepatitis C. | J Med Virol | 2020 | https://conductscience.org/library/papers/30729550 | PubMed |
| 5 | 39898322 | Effects of oral Lcarnitine supplementation on liver enzymes in pediatric acute lymphoblastic leukemia patients in the maintenance phase of treatment: a randomized clinical trial study. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39898322 | PubMed |
| 6 | 34148394 | Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients. | J Vasc Access | 2023 | https://conductscience.org/library/papers/34148394 | PubMed |
| 7 | 37075273 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/37075273 | PubMed |
| 8 | 24820084 | Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24820084 | PubMed |
| 9 | 36944461 | CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine-citrate-heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients. | BMJ Open | 2023 | https://conductscience.org/library/papers/36944461 | PubMed |
| 10 | 16601268 | Cytokines in atherosclerosis: pathogenic and regulatory pathways. | Physiol Rev | 2006 | https://conductscience.org/library/papers/16601268 | PubMed |
| 11 | 34767871 | The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis. | J Hosp Infect | 2022 | https://conductscience.org/library/papers/34767871 | PubMed |
| 12 | 25262758 | Hemodialysis catheter locking solutions and the prevention of catheter dysfunction: a meta-analysis. | J Vasc Access | 2015 | https://conductscience.org/library/papers/25262758 | PubMed |
| 13 | 33394637 | Infusion Therapy Standards of Practice, 8th Edition. | J Infus Nurs | 2021 | https://conductscience.org/library/papers/33394637 | PubMed |
| 14 | 24385746 | MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms. | Turk J Haematol | 2013 | https://conductscience.org/library/papers/24385746 | PubMed |
| 15 | 31145505 | Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology-oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates. | J Paediatr Child Health | 2020 | https://conductscience.org/library/papers/31145505 | PubMed |
| 16 | 27489590 | Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker. | Int J Hematol Oncol Stem Cell Res | 2016 | https://conductscience.org/library/papers/27489590 | PubMed |
| 17 | 19675528 | Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. | Kidney Int | 2009 | https://conductscience.org/library/papers/19675528 | PubMed |
| 18 | 30323092 | Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2018 | https://conductscience.org/library/papers/30323092 | PubMed |
| 19 | 23269457 | Successful prevention of tunneled central catheter infection by antibiotic lock therapy using cefazolin and gentamicin. | Int Urol Nephrol | 2013 | https://conductscience.org/library/papers/23269457 | PubMed |
| 20 | 31712211 | A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/31712211 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41889023 | Effects of Clinical Pharmacist-Led Medication Management on Medication Adherence and Quality of Life in Stroke Patients Undergoing Intravenous Thrombolysis. | Med Sci Monit | 2026 | https://conductscience.org/library/papers/41889023 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41254792
GET https://conductscience.org/api/papers/v1/41254792/references?page=2